Tirzepatide vs Semaglutide: The 2024 Head-to-Head Weight Loss Breakdown

What Are These Drugs?

Semaglutide (brand names Ozempic for diabetes, Wegovy for obesity) is a GLP-1 receptor agonist — it mimics glucagon-like peptide-1, a gut hormone that signals fullness to the brain, slows gastric emptying, and stimulates insulin release in response to meals. It was the original breakthrough drug in this drug class for weight management when the STEP-1 trial was published in 2021.

Tirzepatide (Mounjaro for diabetes, Zepbound for obesity) is a newer dual GIP/GLP-1 receptor agonist, sometimes called a "twincretin." In addition to activating GLP-1 receptors, it also activates receptors for glucose-dependent insulinotropic polypeptide (GIP) — a second incretin hormone. This dual mechanism is what most researchers believe drives tirzepatide's superior weight loss efficacy.

Mechanism Differences: Why Dual Agonism Matters

GLP-1 receptor activation is well understood: it suppresses appetite centrally (in the hypothalamus and brainstem), reduces caloric intake, and improves insulin sensitivity. GIP receptor activation adds a complementary layer. GIP receptors are expressed in adipose tissue and in the central nervous system. When activated, GIP signaling appears to further suppress food intake through pathways that don't fully overlap with GLP-1 — and in animal models, simultaneous GIP + GLP-1 activation produces synergistic rather than merely additive weight loss.

Interestingly, GIP receptors were once considered counterproductive in obesity because GIP was associated with fat storage. The key insight that unlocked tirzepatide's development was that at pharmacological doses, GIP receptor agonism (rather than antagonism) appears to actually reduce fat accumulation and reinforce GLP-1's appetite-suppressing effects. The exact mechanisms are still being elucidated, but the clinical outcomes are unambiguous.

Head-to-Head Trial Data

SURMOUNT-1 (Tirzepatide, 2022)

The landmark SURMOUNT-1 trial enrolled 2,539 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Participants received weekly injections of tirzepatide at 5mg, 10mg, or 15mg — or placebo — over 72 weeks. The results were striking:

• 5mg tirzepatide: average 15.0% body weight reduction
• 10mg tirzepatide: average 19.5% body weight reduction
• 15mg tirzepatide: average 20.9% body weight reduction (some analyses report up to 22.5% with completers)
• 57% of participants on 15mg achieved ≥20% body weight loss vs 1.3% on placebo
• 37% on 15mg achieved ≥25% weight loss — a threshold previously associated only with bariatric surgery

STEP-1 (Semaglutide 2.4mg, 2021)

STEP-1 enrolled 1,961 adults with similar eligibility criteria to SURMOUNT-1. Participants received once-weekly semaglutide 2.4mg (Wegovy dose) or placebo for 68 weeks:

• Average weight loss: 14.9% from baseline body weight
• 31% of participants achieved ≥20% body weight loss
• Significant improvements in waist circumference, lipids, blood pressure, and HbA1c
• Results were considered transformative when published — the drug changed the standard of care for obesity

SURPASS-2 (Tirzepatide vs Semaglutide 1mg in T2D)

SURPASS-2 is the only head-to-head randomized trial between the two drugs, though it used a lower semaglutide dose (1mg, the Ozempic dose for diabetes) in participants with type 2 diabetes. Tirzepatide outperformed semaglutide 1mg on HbA1c reduction and weight loss across all three tirzepatide doses tested. At 15mg, tirzepatide produced 5.5 percentage points greater HbA1c reduction and 7.8 kg more weight loss than semaglutide 1mg. This was conducted in a diabetic population, so extrapolation to obesity-only patients is limited.

SURMOUNT-4 (Tirzepatide Long-Term Maintenance)

SURMOUNT-4 addressed an important clinical question: what happens when you stop the drug? After an initial 36-week open-label period where all participants lost an average of 20.9% body weight, half were randomly assigned to continue tirzepatide and half to switch to placebo. Over the next 88 weeks, the discontinuation group regained two-thirds of the lost weight, while those continuing tirzepatide lost an additional 5.5%. This confirms what clinicians see in practice: weight regain upon stopping is substantial and rapid.

Side Effect Profile Comparison

Both drugs share a largely overlapping side effect profile because both activate GLP-1 receptors. The most common adverse events are gastrointestinal:

Both drugs carry the same label warning regarding a potential risk of medullary thyroid carcinoma and C-cell tumors (based on rodent data; not yet demonstrated in humans) and should not be used in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Pancreatitis has been reported with both; while causality remains debated, both carry pancreatitis warnings on labeling.

Notably, tirzepatide appears to cause somewhat less nausea and vomiting than semaglutide despite producing greater weight loss — a counterintuitive finding that has made it the preferred option for many patients who previously discontinued semaglutide due to GI intolerance.

Cost and Access Considerations

Both drugs are expensive without insurance coverage, and access remains a significant barrier for most patients:

• Wegovy (semaglutide 2.4mg): ~$1,350–$1,500/month list price. Coverage varies widely by insurer; Medicare Part D now covers Wegovy for cardiovascular risk reduction following the SELECT trial results.
• Zepbound (tirzepatide): ~$1,060–$1,200/month list price. Eli Lilly priced Zepbound lower than Wegovy to gain market share. Savings cards available directly through Lilly, reducing costs to $550/month for commercially insured patients.
• Compounded versions: During periods of FDA shortage designation, licensed 503B compounding pharmacies produced compounded semaglutide and tirzepatide at significantly lower costs ($150–$400/month). FDA removed shortage designations for both drugs in 2024, which has substantially reduced the legal availability of compounded versions.
• Telehealth platforms (Ro Body, Calibrate, Henry Meds, Form Health) can provide prescriptions and often work with patients on insurance appeals and prior authorizations.

Who Might Benefit More From Each Drug?

Tirzepatide May Be Preferred When:

• Maximum weight loss is the primary goal and the patient qualifies for the highest dose
• The patient has previously experienced significant nausea or vomiting on semaglutide
• Type 2 diabetes is present alongside obesity (superior glycemic control in SURPASS trials)
• Obstructive sleep apnea is a concurrent issue (SURMOUNT-OSA showed tirzepatide significantly reduced AHI)
• The patient wants the drug with the most robust long-term maintenance data

Semaglutide May Be Preferred When:

• Established cardiovascular disease is present — semaglutide's SELECT trial demonstrated 20% reduction in MACE in non-diabetic patients with obesity and CVD, and this now drives Medicare coverage
• Cost or insurance coverage favors semaglutide (some plans cover Wegovy but not Zepbound, or vice versa)
• The patient has already achieved good results on semaglutide and does not need to switch
• Kidney disease is present — semaglutide's FLOW trial demonstrated renal protection specifically, and this evidence base is stronger for semaglutide than tirzepatide at present
• The patient is pregnant or planning pregnancy (consult physician; neither is approved in pregnancy, but clinical familiarity with semaglutide is greater)

---

Key Trial Evidence at a Glance